RVX-208 Exploratory Study Illustrates Early Potential for Alzheimer's Disease

Calgary, Canada, November 10 (ots/PRNewswire) -

- First in Class Drug Illustrates Early Signal of Transport of
Key Amyloid Marker From Brain

- TSX Exchange Symbol: RVX

Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that
treatment with its lead drug RVX-208, a first in class
ApoA-I/Prebeta-HDL elevating drug, in a post-hoc analysis from the
Phase 1a clinical trial found that treatment with RVX-208 resulted
in a positive trend on an important marker of cognitive function and
Alzheimer's disease, Amyloid-beta40 is an important constituent of
amyloid plaques in the brains of Alzheimer's patients. The analysis
of the plasma markers for Alzheimer's disease was performed by Dr.
D. Larry Sparks, Senior Scientist and Head of the Roberts Laboratory
for Neurodegenerative Disease Research at Sun Health Research
Institute in Sun City, Arizona.

The Phase 1a trial, a double-blind, dose-escalation,
placebo-controlled trial enrolled 24 subjects in three separate
dosing cohorts for a period of one week: 6 received placebo, and 6
received 2mg/kg per day, 6 received 3mg/kg per day and 6 received 8
mg/kg per day of RVX-208. Plasma levels of A- beta (A-beta40) were
measured on day 1 and 7. A 12-14 percent increase in plasma A-beta40
levels was observed at the highest dose of RVX-208 after 7 days of
dosing. Based on the study hypothesis these results trended towards
significance versus placebo, even with the minimal number of study
subjects.

Emerging evidence from large epidemiology studies such as the
Harvard Women's Study, the Honolulu-Asia Aging Study and the
Whitehall II study continue to build support for the relationship
between poor HDL and ApoA-I levels and decreased cognitive function
and Alzheimer's disease. Dr. Sparks's investigation of elective
statin use and fractionated cholesterol levels in the ADAPT cohort
has identified a significant relationship between elevated HDL levels
and better performance on the Mini Mental State Examination (MMSE),
and a significant inverse relationship between increased total and
LDL cholesterol and learning and memory. Elevated cholesterol levels
are thought to increase the production and accumulation of the
putative AD neurotoxin, amyloid-beta (A-beta). The A-beta peptide is
produced by aberrant cleavage of a larger precursor protein resulting
in two lengths, either 42 or 40 amino acids long.

"Stemming from RVX-208's effects on ApoA-I, Prebeta-HDL
production and the facilitation of reverse cholesterol transport, we
hypothesized that RVX- 208 might increase circulating A-beta40 levels
through its effects on functional HDL, which can act as a sponge to
draw A-beta40 from the brain to the circulation, for enhanced
clearance from the body," stated Dr. Sparks. "Although it was a pilot
study, with minimal subjects, we were pleased to find a positive
signal and look forward to performing further research on RVX-208 in
this critical area of unmet medical need," Dr. Sparks added.

"We are pleased and cautious about these early results," stated
Kenneth Lebioda, Senior Vice President of Business and Corporate
Development of Resverlogix. "This data provides important evidence
solidifying our strategy to continue research efforts in this
important disease area. We have always maintained a strategic life
cycle management strategy that ensures the pursuit of important
research in areas of critical unmet need. Our progress in Alzheimer's
disease research illustrates our commitment to build a broad
portfolio of opportunities in areas of unmet need for our lead drug
and our NexVas(TM) platform technology. We look forward to continue
our research collaboration with Dr. Sparks in this important medical
area."

About RVX-208

RVX-208, a first in class novel small molecule therapeutic that
facilitates endogenous Apolipoprotein A-I (ApoA-I) production, is
positioned to be one of the most promising emerging drugs in the
treatment of atherosclerosis and vascular disorders such as
Alzheimer's disease, vascular dementia, stroke, and Peripheral Artery
Disease (PAD). ApoA-I, the critical cardioprotective protein of
high-density lipoprotein (HDL) represent the bodies natural defense
system against atherosclerosis by mediating reverse cholesterol
transport (RCT), the transport of peripheral cholesterol including
that of the vessel wall to the liver for processing. To the Company's
knowledge RVX-208 is the only novel small molecule that is
specifically designed to increase ApoA-I production and thereby raise
Prebeta-HDL levels thus enhancing HDL functionality to augment
reverse cholesterol transport (RCT) from vascular beds.

About Alzheimer's Disease

Every 71 seconds, someone in America develops Alzheimer's disease
(AD) and it is estimated that by mid-century, someone will develop
Alzheimer's every 33 seconds. Neurodegenerative diseases such as
Alzheimer's are one of the most debilitating in the developed world
with an estimated prevalence in the United States which is expected
to grow to 15 million people by 2050. In a report commissioned by the
Alzheimer's Association, caregiver costs in the United States are
estimated at US$36.5 billion which includes loss of productivity,
absenteeism and worker replacement. The indirect costs of AD would
also be greatly reduced; it is estimated that one-half to two-thirds
of the cost of AD care stems from unpaid caregivers (often family
members), who spend 16-35 hours per week looking after a person with
AD. These figures underscore the importance of developing new
therapies to aide in the socioeconomic burden of AD.

About Sun Health Research Institute

For 21 years, Sun Health Research Institute, part of nonprofit
Banner Health, has been a leader nationally and internationally in
the effort to find answers to disorders of aging including
Alzheimer's disease, Parkinson's disease, arthritis and prostate
cancer. The institute, together with its Arizona Alzheimer's
Consortium partners, has been designated by the National Institutes
of Health as one of just 31 Alzheimer's disease Centers in the
nation.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in
the development of novel therapies for important global medical
markets with significant unmet needs. The NexVas(TM) PR program is
the Company's primary focus which is to develop novel small molecules
that enhance ApoA-I. These vital therapies address the grievous
burden of atherosclerosis and other important diseases such as acute
coronary syndrome, diabetes, Alzheimer's disease, Peripheral Artery
Disease and other vascular disorders. The Company's secondary focus
is TGF-Beta Shield(TM), a program that aims to address burgeoning
grievous diseases, such as cancer and fibrosis. Resverlogix Corp.
trades on the Toronto Stock Exchange (TSX:RVX). For further
information please visit http://www.resverlogix.com.

This news release may contain certain forward-looking statements
that reflect the current views and/or expectations of Resverlogix
Corp. with respect to its performance, business and future events.
Such statements are subject to a number of risks, uncertainties and
assumptions. Actual results and events may vary significantly. The
TSX Exchange does not accept responsibility for the adequacy or
accuracy of this news release.

ots Originaltext: Resverlogix Corp.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
For further information: Theresa Kennedy, VP, Corporate
Communications, Resverlogix Corp., Phone: +1-604-538-7072, Fax:
+1-403-256-8495, Email: Theresa@resverlogix.com; Sarah Zapotichny,
Manager, Investor Relations, Resverlogix Corp., Phone:
+1-403-254-9252, Fax: +1-403-256-8495, Email: Sarah@resverlogix.com